HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

EU cosmetic labeling

This article was originally published in The Rose Sheet

Executive Summary

Deadline for durability labeling of cosmetic products with a life of more than 30 months went into effect March 11, the EU Commission reminds industry and consumers in a same day statement. Provision requires products to indicate the time period by which the item must be used after opening using a symbol of an open beauty cream jar followed by the period of use after opening. "The motivation behind this initiative is to better inform consumers, given some cosmetics can deteriorate after opening and be possibly harmful to the consumer," Commission states. Labeling of 26 fragrance allergens used in fragrances in cosmetic products also is mandatory as of March 11. New labeling requirements follow the adoption of the directive in 2003 by the European Parliament and the Council (1"The Rose Sheet" Feb. 17, 2003, In Brief)...

You may also be interested in...



FDA Contracts For QRA Model To Determine Safe Use Levels For 26 Fragrance Allergens

The ingredients at issue already must be labeled on cosmetic products in the EU due to their recognized sensitization and allergy potential. FDA expects to award the contract by the end of September, and finished work will be due to the agency within 18 months thereafter.

EU animal testing

Council of Ministers adopts Seventh Amendment to the Cosmetics Directive banning animal testing on cosmetics. Legislation, passed during the Council's Jan. 27-28 meeting, is in line with joint text agreed upon in conciliation with European Parliament, which passed the amendment Jan. 15. Long-debated marketing/testing ban passed conciliation in November prohibiting testing of cosmetics on animals immediately when alternative methods are available and imposing a six-year deadline for most tests when validated alternatives are not yet available (1"The Rose Sheet" Nov. 25, 2002, p. 6)...

Roche Continues To Make The Case For Gantenerumab In Alzheimer’s Disease

The amyloid-targeting drug is years behind Biogen/Eisai’s aducanumab, but its subcutaneous administration and the GRADUATE studies’ design could give Roche’s gantenerumab an advantage.

UsernamePublicRestriction

Register

RS012892

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel